Actinogen Medical Limited (AU:ACW) has released an update.
Actinogen Medical has reported promising outcomes from their phase 2a XanaCIDD depression trial, showing that their drug Xanamem notably improved depressive symptoms. The 10 mg dose of Xanamem demonstrated a substantial and sustained antidepressant effect, with maximum benefits observed at Week 10. The company is now exploring future treatment pathways for Major Depressive Disorder in collaboration with regulators and potential partners.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.
